Table 2 Prognostic values of clinical variables for predicting progression-free survival in 184 patients with metastatic renal cell carcinoma (including continuous variables) analyzed by using univariate and multivariate Cox regression models
Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Sex (men vs. women) | 1.097 (0.764–1.575) | 0.616 |  |  |
Age (<65 vs. ≥65 years) | 1.005 (0.990–1.020) | 0.535 |  |  |
Pathologic type (ccRCC vs. nccRCC) | 1.081 (0.690–1.694) | 0.733 |  |  |
History of nephrectomy (yes vs. no) | 1.180 (0.790–1.762) | 0.418 |  |  |
History of cytokine treatment (yes vs. no) | 1.249 (0.896–1.742) | 0.190 |  |  |
Fuhrman grade (1–2 vs. 3–4 and unknown) | 1.298 (1.031–1.633) | 0.027* | 1.211 (0.951–1.542) | 0.121 |
Number of metastatic sites (1 vs. ≥ 2) | 1.763 (1.255–2.476) | 0.001* | 1.576 (1.092–2.274) | 0.015 |
MSKCC risk category (favorable and intermediate vs. poor) | 1.927 (1.548–2.399) | <0.001* | 1.957 (1.558–2.460) | 0.004 |
NLR (continuous variable) | 1.133 (1.061–1.209) | <0.001* | 1.103 (1.032–1.178) | 0.004 |
Drug category (sorafenib vs. sunitinib) | 1.020 (0.739–1.408) | 0.905 |  |  |
Pre-treatment serum albumin level (continuous variable) | 0.975 (0.949–1.003) | 0.075 |  |  |
Post-treatment serum albumin level (continuous variable) | 0.961 (0.941–0.982) | <0.001* | 0.975 (0.952–0.999) | 0.042 |